Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma (MREO) Equity Average (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Equity Average for 3 consecutive years, with $50.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average rose 1548.27% to $50.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $50.4 million, a 1548.27% increase, with the full-year FY2024 number at $55.8 million, up 9.39% from a year prior.
  • Equity Average was $50.4 million for Q3 2025 at Mereo BioPharma, down from $57.1 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $60.7 million in Q2 2024 to a low of -$5.8 million in Q4 2024.
  • A 3-year average of $43.0 million and a median of $50.4 million in 2025 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: tumbled 110.99% in 2024, then skyrocketed 1548.27% in 2025.
  • Mereo BioPharma's Equity Average stood at $52.6 million in 2023, then crashed by 110.99% to -$5.8 million in 2024, then skyrocketed by 971.23% to $50.4 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Equity Average are $50.4 million (Q3 2025), $57.1 million (Q2 2025), and $60.5 million (Q1 2025).